Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiotherapy for the Treatment of Oligometastatic Tumors versus Standard of Care

Background: Recent clinical trial results reported that stereotactic radiotherapy (SABR) may improve survival for patients with oligometastatic (OM) cancer. Given that these results come from a phase II trial, there remains considerable uncertainty about this finding, and about the cost-effectivenes...

Descripción completa

Detalles Bibliográficos
Autores principales: Raymakers, Adam J. N., Cameron, David, Tyldesley, Scott, Regier, Dean A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161824/
https://www.ncbi.nlm.nih.gov/pubmed/34068400
http://dx.doi.org/10.3390/curroncol28030172

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161824/
https://www.ncbi.nlm.nih.gov/pubmed/34068400
http://dx.doi.org/10.3390/curroncol28030172

Ejemplares similares